中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

66 records (took 0.04 seconds)

    Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
    3.
    发明授权
    Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof 有权

    公开(公告)号：US10428149B2

    公开(公告)日：2019-10-01

    申请号：US15558372

    申请日：2016-03-18

    Applicant: UNIVERSITÄT STUTTGART ,  BIONTECH AG

    Inventor： Ugur Sahin ,  Roland Kontermann ,  Klaus Pfizenmaier ,  Martin Siegemund ,  Meike Hutt ,  Oliver Seifert

    IPC: C07K16/32 ,  C07K16/28 ,  C07K14/705

    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.

    AGONISTIC TNF RECEPTOR BINDING AGENTS
    6.
    发明申请
    AGONISTIC TNF RECEPTOR BINDING AGENTS 审中-公开

    公开(公告)号：US20180194849A1

    公开(公告)日：2018-07-12

    申请号：US15538419

    申请日：2016-01-08

    Applicant: BIONTECH AG ,  GENMAB A/S

    Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

    IPC: C07K16/28

    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

    Identification of tumor-associated cell surface antigens for diagnosis and therapy
    10.
    发明授权
    Identification of tumor-associated cell surface antigens for diagnosis and therapy 有权

    公开(公告)号：US09267177B2

    公开(公告)日：2016-02-23

    申请号：US14830506

    申请日：2015-08-19

    Applicant: BioNTech AG

    Inventor： Özlem Türeci ,  Ugur Sahin ,  Gerd Helftenbein ,  Volker Schlüter

    IPC: C12Q1/68

    CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

    Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

Patent Agency Ranking